Prediagnostic White Blood Cell DNA Methylation and Risk of Breast Cancer in the Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort.
Aged
Breast Neoplasms
/ genetics
Case-Control Studies
Cell Cycle Proteins
/ genetics
CpG Islands
DNA Methylation
DNA-Binding Proteins
/ genetics
Endonucleases
/ genetics
Female
Humans
Intracellular Signaling Peptides and Proteins
/ genetics
Leukocytes
Membrane Proteins
/ genetics
Membrane Transport Proteins
/ genetics
Middle Aged
Mitochondrial Proteins
/ genetics
Prospective Studies
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
10
12
2020
revised:
11
03
2021
accepted:
21
05
2021
pubmed:
11
6
2021
medline:
25
2
2022
entrez:
10
6
2021
Statut:
ppublish
Résumé
White blood cell (WBC) DNA may contain methylation patterns that are associated with subsequent breast cancer risk. Using a high-throughput array and samples collected, on average, 1.3 years prior to diagnosis, a case-cohort analysis nested in the prospective Sister Study identified 250 individual CpG sites that were differentially methylated between breast cancer cases and noncases. We examined five of the top 40 CpG sites in a case-control study nested in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. We investigated the associations between prediagnostic WBC DNA methylation in 297 breast cancer cases and 297 frequency-matched controls. Two WBC DNA specimens from each participant were used: a proximate sample collected 1 to 2.9 years and a distant sample collected 4.2-7.3 years prior to diagnosis in cases or the comparable timepoints in controls. WBC DNA methylation level was measured using targeted bisulfite amplification sequencing. We used logistic regression to obtain ORs and 95% confidence intervals (CI). A one-unit increase in percent methylation in There was no convincing pattern between percent methylation in the five CpG sites and breast cancer risk. The link between prediagnostic WBC DNA methylation marks and breast cancer, if any, is poorly understood.
Sections du résumé
BACKGROUND
White blood cell (WBC) DNA may contain methylation patterns that are associated with subsequent breast cancer risk. Using a high-throughput array and samples collected, on average, 1.3 years prior to diagnosis, a case-cohort analysis nested in the prospective Sister Study identified 250 individual CpG sites that were differentially methylated between breast cancer cases and noncases. We examined five of the top 40 CpG sites in a case-control study nested in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort.
METHODS
We investigated the associations between prediagnostic WBC DNA methylation in 297 breast cancer cases and 297 frequency-matched controls. Two WBC DNA specimens from each participant were used: a proximate sample collected 1 to 2.9 years and a distant sample collected 4.2-7.3 years prior to diagnosis in cases or the comparable timepoints in controls. WBC DNA methylation level was measured using targeted bisulfite amplification sequencing. We used logistic regression to obtain ORs and 95% confidence intervals (CI).
RESULTS
A one-unit increase in percent methylation in
CONCLUSIONS
There was no convincing pattern between percent methylation in the five CpG sites and breast cancer risk.
IMPACT
The link between prediagnostic WBC DNA methylation marks and breast cancer, if any, is poorly understood.
Identifiants
pubmed: 34108140
pii: 1055-9965.EPI-20-1717
doi: 10.1158/1055-9965.EPI-20-1717
doi:
Substances chimiques
CAVIN3 protein, human
0
Cell Cycle Proteins
0
DNA-Binding Proteins
0
Intracellular Signaling Peptides and Proteins
0
MCUR1 protein, human
0
Membrane Proteins
0
Membrane Transport Proteins
0
Mitochondrial Proteins
0
OPTN protein, human
0
ERCC1 protein, human
EC 3.1.-
Endonucleases
EC 3.1.-
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1575-1581Informations de copyright
©2021 American Association for Cancer Research.
Références
Foley DL, Craig JM, Morley R, Olsson CJ, Dwyer T, Smith K, et al. Prospects for epigenetic epidemiology. Am J Epidemiol. 2009;169:389–400.
Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, et al. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther. 2004;3:1225–31.
Campan M, Weisenberger DJ, Laird PW. DNA methylation profiles of female steroid hormone-driven human malignancies. Curr Top Microbiol Immunol. 2006;310:141–78.
Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21:5400–13.
Xu Z, Sandler DP, Taylor JA. Blood DNA methylation and breast cancer: a prospective case-cohort analysis in the sister study. J Natl Cancer Inst. 2020;112:87–94.
van Veldhoven K, Polidoro S, Baglietto L, Severi G, Sacerdote C, Panico S, et al. Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics. 2015;7:67.
Severi G, Southey MC, English DR, Jung CH, Lonie A, McLean C, et al. Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat. 2014;148:665–73.
Garcia-Closas M, Gail MH, Kelsey KT, Ziegler RG. Searching for blood DNA methylation markers of breast cancer risk and early detection. J Natl Cancer Inst. 2013;105:678–80.
Xu Z, Bolick SC, Deroo LA, Weinberg CR, Sandler DP, Taylor JA. Epigenome-wide association study of breast cancer using prospectively collected sister study samples. J Natl Cancer Inst. 2013;105:694–700.
Masser DR, Berg AS, Freeman WM. Focused, high accuracy 5-methylcytosine quantitation with base resolution by benchtop next-generation sequencing. Epigenetics Chromatin. 2013;6:33.
Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21:273S–309S.
Olova N, Krueger F, Andrews S, Oxley D, Berrens RV, Branco MR, et al. Comparison of whole-genome bisulfite sequencing library preparation strategies identifies sources of biases affecting DNA methylation data. Genome Biol. 2018;19:33–2.
Masser DR, Stanford DR, Freeman WM. Targeted DNA methylation analysis by next-generation sequencing. J Vis Exp. 2015;96:52488.
Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for bisulfite-seq applications. Bioinformatics. 2011;27:1571–2.
Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. Nat Methods. 2012;9:357–9.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.
SekMonk: a tool to visualise and analyse high throughput mapped sequence data [homepage on the Internet]. 2017.
Lacey JV Jr, Kreimer AR, Buys SS, Marcus PM, Chang SC, Leitzmann MF, et al. Breast cancer epidemiology according to recognized breast cancer risk factors in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial cohort. BMC Cancer. 2009;9:84.
Bodelon C, Ambatipudi S, Dugue PA, Johansson A, Sampson JN, Hicks B, et al. Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies. Breast Cancer Res. 2019;21:62–9.
Wong EM, Southey MC, Terry MB. Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer. Br J Cancer. 2020;122:1133–40.
Sandler DP, Hodgson ME, Deming-Halverson SL, Juras PS, D'Aloisio AA, Suarez LM, et al. The Sister Study cohort: baseline methods and participant characteristics. Environ Health Perspect. 2017;125:127003.